Zimbabwe has rejected a substantial US health deal worth $367m (272 million pounds) over five years over the United States' request for confidential data.
The decision came to light following a official document from December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "skewed".
An official spokesman later stated that the United States was seeking biological samples for scientific study and commercial purposes while refused to guarantee the benefits from any future treatments.
"We will now turn to the challenging and unfortunate task of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for further negotiations to secure a agreement suitable to all parties so the nation's vital HIV programme can proceed.
Wider Implications
This rejection follows a similar case in Kenya, where a court suspended a similar health funding agreement after legal challenges were raised about the security of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump claimed its spending was "inefficient" and his government was seeking direct bilateral deals to enhance openness and accountability.
As per statements, 16 African countries have to date agreed to similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment through American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, without any equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Effectively, our country would provide the basic resources for medical research with no assurance that the resulting innovations would be accessible to our citizens if a new disease outbreak arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending structures previously set up via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future pandemics.
"This mechanism is intended to ensure that when a nation provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to further discussions with our American counterparts on how future collaboration might be arranged in a manner that honours the sovereignty and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but recommended that talks must proceed since a large portion of the country's Aids initiatives were funded by international support.
"In cases where specific concerns exist, such as those involving data governance or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," the group said.
The situation emphasises the ongoing tensions between receiving vital international aid and protecting local interests in an increasingly data-driven world.